Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 470

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 470
---
 taxes:

| (€ million)                                                             |   2024 |   2023 | -a |   2022 | -a |
| Current taxes                                                           | -2,152 | -2,251 |    | -2,631 |    |
| Deferred taxes                                                          |    948 |  1,234 |    |    722 |    |
| Total                                                                   | -1,204 | -1,017 |    | -1,909 |    |
| Income before tax and investments accounted for using the equity method |  6,698 |  6,251 |    |  9,937 |    |

(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

| F-92 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as

follows:

| (%)                                                                                   |  2024 |  2023 | -a | 2022 | -a |
| Standard tax rate applicable in France                                                |  25.8 |  25.8 |    | 25.8 |    |
| Difference between the standard French tax rate and the rates applicable to Sanofi(b) | -13.3 | -15.3 |    | -6.9 |    |
| Revisions to tax exposures and settlements of tax disputes                            |   2.8 |   3.1 |    | -0.8 |    |
| Fair value remeasurement of contingent consideration                                  |       |   0.1 |    | -0.2 |    |
| Other items(c)                                                                        |   2.7 |   2.6 |    |  1.3 |    |
| Effective tax rate                                                                    |  18.0 |  16.3 |    | 19.2 |    |

(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

(b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many

countries, most of which have lower tax rates than France. For the year ended December